Učitavanje...
Management of Docetaxel Failures in Metastatic Castrate-Resistant Prostate Cancer
The treatment of metastatic castration resistant prostate cancer (mCRPC) has evolved markedly since the approval of docetaxel-based therapy in 2004. Since that time, 3 distinct agents have gained approval for use in the mCRPC setting, namely sipuleucel-T, cabazitaxel and abiraterone. Even more recen...
Spremljeno u:
| Glavni autori: | , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2012
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3845898/ https://ncbi.nlm.nih.gov/pubmed/23084533 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ucl.2012.07.013 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|